

Thermo Fisher, PharmaFluidics enter into strategic agreement

01 October 2018 | News

The agreement empowers PharmaFluidics to sell Thermo Fisher custom-made EASY-Spray transfer lines, in combo sets with PharmaFluidics' own line of µPAC chromatography micro-Chips, to constitute an ultra-high-resolution front-end source platform for Thermo Fisher mass spectrometry (MS) instruments.



PharmaFluidics NV, an innovative bio-analytical chromatography company, has entered into a Partnership Agreement with Thermo Fisher Scientific Inc, a global Life Sciences Tools and Instruments leader. The agreement empowers PharmaFluidics to sell Thermo Fisher custom-made EASY-Spray transfer lines, in combo sets with PharmaFluidics' own line of μ PAC chromatography micro-Chips, to constitute an ultra-high-resolution front-end source platform for Thermo Fisher mass spectrometry (MS) instruments.

The μ PAC Pillar Array Chromatography technology is an innovative platform that provides high-quality separation capabilities for MS. Using propietary micro-Chip microfluidic technology, the μ PAC achieves superior separation of components in complex biological samples, improving LC-MS analysis results. The combined capabilities are revolutionizing the analysis of biological samples, allowing researchers, developers and vendors to keep pace in the buoyant and emerging fields of proteomics and protein-based diagnostics.

"This is an exciting opportunity to facilitate our µPAC customers' proteome analysis workflows and raise their protein identification performance capabilities to new heights," said Katrien Vanhonacker, Vice President Business Development at PharmaFluidics. "It will provide all users of Thermo Scientific™ EASY-Spray source-equipped mass spectrometers with familiar access and connections to PharmaFluidics' separation chip."